20 results about "Malignant effusion" patented technology

The invention discloses a construction method of a malignant pleural effusion prediction model, a marker combination and application, equipment and a medium. The construction method comprises the following steps: S1, obtaining characteristics of a biomarker combination; the biomarker combination is composed of three biomarkers of NGAL, CEA and CA50; s2, based on the characteristics of the biomarker combination, adopting Logistic regression analysis to respectively construct regression models corresponding to the three biomarkers, and respectively outputting parameters alpha NGAL, beta NGAL, alpha CEA, beta CEA, alpha CA50 and beta CA50; and S3, based on the output parameters in the step S2, adopting Bayesian analysis to construct a malignant pleural effusion prediction model. The method can be used for predicting the MPE probability in the pleural effusion patient, the identification and prediction accuracy is high, and compared with pleural biopsy and thoracoscopic sampling biopsy, the method has the advantages of being rapid, minimally invasive and the like.

The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine preparation for treating pleural effusion and peritoneal effusion and a preparation method thereof.The traditional Chinese medicine preparation is prepared from, by weight, 10-50 parts of traditional Chinese medicine extract, 30-70 parts of filler, 5-20 parts of enteric coating material, 5-15 parts of HPMC, 0.5-2 parts of triethyl citrate and 0.25-1.5 parts of magnesium stearate; poria cocos, polyporus umbellatus, rhizoma alismatis, astragalus membranaceus, curcuma zedoary, cassia twig, oldenlandia diffusa, sculellaria barbata, semen coicis and traditional Chinese medicine extracts are used as cores, the stability of volatile drugs is improved through an inclusion technology, and the volatile drugs are entrapped in a pH intelligent response type enteric coating material composed of aromatic ring-containing vinyl monomers, ethyl acrylate, DMAEMA and MAA. The traditional Chinese medicine preparation has the synergistic effect of efficiently inducing diuresis, activating blood circulation and eliminating tumors and enteric-coated long-acting directional delivery, and is suitable for patients with pleural effusion and peritoneal effusion, especially malignant effusion.

The invention relates to the technical field of conveying, in particular to a visual inspection type malignant pleural effusion treatment pill production material guiding mechanism which comprises a rack, a material guiding box, a visual inspection head fixed to the material guiding box and a box cover, the rack is provided with a driving mechanism, the material guiding box is connected with the driving mechanism through a damping assembly, and the box cover is connected with the visual inspection head. The box cover is arranged on the material guiding box in a sliding mode through an elastic assembly, the material guiding box is provided with an opening assembly matched with the material pouring trigger rod, the material loading trigger rod and the box cover, and the material guiding box is further provided with an overturning assembly matched with the box cover and the damping assembly. The driving mechanism is matched with the damping assembly to enable the guide box to keep stable in reciprocating translation, so that pill damage is reduced; the box cover is normally sealed under the action of the elastic assembly and is only opened under the action of the trigger rod, dust is prevented from escaping, and clean production is guaranteed; the overturning assembly is in linkage with the material guiding box to overturn at the moment of sliding of the box cover, fixed-point quantitative material pouring is achieved, and the process automation degree is improved.

The invention discloses a construction method and application of a heart failure / malignant / pneumonia-paracenopneumonic / tuberculous pleural effusion screening model. The construction method comprises the step of respectively constructing a heart failure pleural effusion screening model, a malignant pleural effusion screening model, a parapneumonia pleural effusion screening model and a tuberculous pleural effusion screening model by adopting a Logistic regression analysis method based on a biomarker combination. According to the invention, a screening model is constructed by combining biomarkers containing 11 amino acids, so as to assist in identifying various types of pleural effusion.

The invention relates to the technical field of tumor immunotherapy, in particular to an HLA-A * 11: 01 restrictive neoantigen peptide based on malignant pleural effusion tumor cells and application of the HLA-A * 11: 01 restrictive neoantigen peptide. The tumor neoantigen polypeptide is separated and screened from malignant pleural effusion of a lung cancer patient, and the amino acid sequence of the neoantigen polypeptide is shown as any one of SEQ ID NO.1-9. The tumor neoantigen polypeptide has high affinity with HLA molecules, can stimulate generation of tumor specific T cells, and can be used as a target spot for clinical treatment or diagnosis of tumors. The invention also provides a method for separating and screening the tumor neoantigen polypeptide, the method solves the problem that the neoantigen of a non-surgical treatment patient cannot be obtained, and an effective method is provided for the development of the tumor neoantigen polypeptide.

The invention discloses a multi-omics malignant pleural effusion immunometabolism reprogramming spatio-temporal heterogeneity analysis device, which comprises an integration analysis module used for carrying out multi-modal integration and consensus clustering analysis on a multi-omics data set to obtain an integration analysis result, dividing the malignant pleural effusion training samples of the malignant pleural effusion patient into an immunometabolism activation type subtype, an immunometabolism transition type subtype and an immunometabolism inhibition type subtype according to the confluence analysis result; the screening construction module is used for screening immune metabolism markers from the characteristics of the immune metabolism inhibition type subtypes, forming a candidate target point set according to the immune metabolism markers, and constructing a prediction model; and the evaluation suggestion module is used for calculating treatment response scores and combining the treatment response scores with the clinical staging information to construct a column diagram, and a prognosis risk evaluation result and personalized treatment guidance suggestions are obtained, so that the accuracy of prognosis evaluation and the reliability of treatment response prediction can be improved, and accurate risk stratification and personalized treatment guidance for patients can be realized.

The invention relates to application of a protein heterodimer in preparation of a medicine. The medicine is used for preventing and / or treating malignant effusion. The present invention relates to a protein heterodimer comprising a first member and a second member different from the first member wherein the first member comprises a light chain and a heavy chain, the heavy chain comprising a first Fc region, the light chain complexed with the heavy chain to form a targeting moiety exhibiting binding specificity for tumor antigens; the second member comprises a polypeptide comprising an immunomodulator fused to a second Fc region; the first member and the second member are associated by recombination of the first Fc region and the second Fc region to form the heterodimer; and the first Fc region comprises a first modification and / or the second Fc region comprises a second modification, which modifications are more effective to promote heterodimerization between the first member and the second member.

This invention discloses a multi-omics device for analyzing the spatiotemporal heterogeneity of immunometabolic reprogramming in malignant pleural effusion. The device includes an integration analysis module for performing multimodal integration and consensus clustering analysis on multi-omics datasets to obtain integration analysis results. Based on the integration analysis results, the training samples of malignant pleural effusion from patients are classified into three subtypes: immunometabolic activation, immunometabolic transition, and immunometabolic inhibition. A screening and construction module is used to screen immunometabolic biomarkers from the features of the immunometabolic inhibition subtype, construct a candidate target set based on these biomarkers, and build a prediction model. An assessment and suggestion module is used to calculate treatment response scores and integrate clinical staging information to construct a nomogram, obtaining prognostic risk assessment results and personalized treatment guidance suggestions. This improves the accuracy of prognostic assessment and the reliability of treatment response prediction, enabling precise risk stratification and personalized treatment guidance for patients.

The invention discloses a research method for detecting malignant pleural effusion by using flow cytometry, which comprises the following steps: detecting the expression of CD169 + macrophages in clinical postoperative pleural effusion, inflammatory pleural effusion and malignant pleural effusion samples and MPE modeling mice by using a flow cytometry technology, and analyzing with the effective control rate of the pleural effusion. Expression of immune checkpoints of CD169 + macrophages in MPE and a mechanism causing poor effective control rate of pleural effusion are further analyzed, and a certain basis is provided for determining a new target spot for MPE treatment.

The invention relates to the technical field of external treatment of traditional Chinese medicines, discloses a traditional Chinese medicine hot compress bag for improving malignant hydrothorax and ascites and a preparation method and application of the traditional Chinese medicine hot compress bag, and aims to overcome the defects that an existing preparation is poor in syndrome differentiation adaptability, low in transdermal efficiency and high in effusion recurrence rate. And the three-layer composite outer bag is filled with the mixture. The basic medicine powder strengthens the body resistance, promotes blood circulation and diuresis, the medicine powder is added or reduced to adapt to different syndromes such as spleen deficiency and excessive dampness, the heating substrate controls temperature and promotes permeation, and the outer bag guarantees the medicine effect and use safety. The preparation process is simple and convenient, the plaster is heated and applied to corresponding acupoints during use, symptoms are relieved in a targeted manner, the effusion absorption efficiency is improved, the recurrence rate is reduced, operation is convenient and fast, and the plaster is suitable for home and primary medical treatment and remarkably improves the life quality of patients.

The present invention relates to the field of medical technology, and more particularly to a pyruvate inhalation atomizer for treating malignant pleural effusion caused by lung cancer and a preparation method thereof. The pyruvate inhalation atomizer comprises the following raw materials in percentage by mass: 0.05-0.08% compound A, 0.05-0.1% sodium pyruvate, 0.2-2% disodium hydrogen phosphate, 0.2-2% sodium dihydrogen phosphate, and the balance normal saline; the structural formula of the compound A is as follows: #imgabs0#. Research results indicate that the pyruvate inhalation atomizer can alleviate the symptoms of malignant pleural effusion caused by lung cancer by reducing the amount of pleural effusion in MPE model mice, as well as upregulating the expression of IL-7 and downregulating the expression of VEGF in serum.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine plaster formula targeting tumor acupoints and application of the traditional Chinese medicine plaster formula, the traditional Chinese medicine plaster formula is composed of 24 traditional Chinese medicines such as musk, oldenlandia diffusa and sculellaria barbata, the scheme deeply integrates traditional Chinese medicine transdermal absorption and meridian targeting tropism mechanisms, and the limitation that traditional external treatment neglects overall differentiation is broken through. According to the preparation process, through segmented treatment and low-temperature reaction, the sensitization risk of minium is remarkably reduced, the anti-tumor curative effect can be synergistically enhanced, cancer pain can be relieved, malignant effusion can be controlled, particularly, the dosage of western medicines can be reduced and toxic and side effects can be reduced when the medicine is combined with radiotherapy and chemotherapy, and a safe and effective adjuvant therapy means is provided for tumor patients.

The present invention provides methods of producing, from malignant pleural effusion, expanded populations of tumour tissue-resident T cell memory (Trm) like CD103+CD8+ T cells based on expression of GPR183 and CXCR4 or expression of LITAF, JUNB and PI3KR1. Also provided are uses of said cells as a medicament and as a prognostic marker.

The present application relates to the technical field of tumor immunotherapy, and particularly relates to HLA-A*11:01 restricted neoantigen peptides based on malignant pleural effusion tumor cells and application thereof. The present application obtains tumor neoantigen polypeptides by separating and screening from malignant pleural effusion of lung cancer patients, the amino acid sequence of the neoantigen polypeptides is shown in any one of SEQ ID NO. 1-9; the tumor neoantigen polypeptides have high affinity with HLA molecules, can stimulate tumor-specific T cells, and can be used as a target for tumor clinical treatment or diagnosis. The present application further provides a method for separating and screening tumor neoantigen polypeptides, which solves the problem that the neoantigen of non-surgical treatment patients cannot be obtained, and provides an effective method for development of tumor neoantigen polypeptides.

The invention provides an establishment method of a lung cancer 2.5 D organ phenotype plasticity transformation model. The establishment method comprises the following steps: step S1, obtaining a malignant pleural effusion sample of a lung cancer patient; s2, performing 2.5 D organoid culture on the sample to form a suspended phenotype organoid; s3, converting the organoid from a suspension phenotype to a wall-attaching phenotype; S4, converting the organoid from the wall-attaching phenotype to the suspension phenotype; s5, repeating the step S3 and the step S4 to realize multiple cycles of phenotypic transformation; and S6, identifying genetic feature differences. The invention relates to the technical field of organoid, and successfully establishes a lung cancer 2.5 D organoid phenotype plasticity transformation model, the model overcomes a plurality of defects of a traditional in-vitro model, can more truly simulate phenotype change of lung cancer cells in an in-vivo microenvironment, and has a good application prospect. And an innovative and effective research platform is provided for researching the drug resistance and metastasis mechanism driven by the phenotype plasticity of the tumor cells.

This invention discloses a cell cluster separation device and its usage method in malignant pleural effusion, belonging to the field of cell separation technology. By having two locking blocks approach each other and disengage from the locking groove, the locking state between the support base and the mounting base is released, allowing the support base and multiple centrifuge tubes to be removed from the centrifuge. When removing the centrifuge tubes, because the central axis of the tube rack and the support base is parallel, the centrifuge tubes can be directly pulled vertically upwards, facilitating the simultaneous removal of multiple centrifuge tubes. The downward movement of the conical seat can compress the two locking blocks, causing them to engage in the locking groove, thus achieving the purpose of locking the support base and the mounting base. Therefore, the modular design of the centrifuge, support base, and tube rack enables the rapid loading and unloading of batches of centrifuge tubes. The use of two sets of support bases and multiple tube racks for centrifugation allows for alternating loading and unloading of centrifuge tubes, shortening the time spent loading and unloading centrifuge tubes and facilitating the efficient and stable separation of cell clusters.

The invention relates to the field of biomedicine, and discloses a construction method and application of CIC rearrangement sarcoma primary cells. The construction method comprises the following steps: acquiring a malignant pleural effusion sample of a CIC rearrangement sarcoma patient; centrifuging the pleural effusion sample, and separating to obtain cell precipitate; cleaning the cell precipitate, lysing red blood cells, and centrifuging to obtain CIC rearranged sarcoma cells; and resuspending the CIC rearranged sarcoma cells in a cell culture solution, filtering, and culturing to obtain the CIC rearranged sarcoma primary cells. The technical bottleneck of CIC rearrangement sarcoma primary modeling is successfully broken through, and the established cell line and the related culture technology thereof have important scientific research and clinical transformation values. Besides, development of an animal model constructed based on the cell line and related diagnostic reagents is expected to provide key technical support for precise diagnosis and treatment of the rare sarcoma, and the cell line has remarkable social benefits and application prospects.

The invention discloses a drainage and drug delivery integrated system for malignant pleural effusion and a control method thereof.The drainage and drug delivery integrated system comprises a catheter assembly, the catheter assembly comprises a catheter body, one end of the catheter body is a thoracic cavity end, and the other end of the catheter body is an in-vitro end; an inner cavity of the tube body is divided into a drainage cavity, a dosing cavity and a sampling cavity; the in-vitro connecting unit comprises a drainage device, a dosing device and a sampling device; the drainage device is communicated with the drainage cavity through the drainage tube to form a drainage loop; the dosing device is communicated with the dosing cavity through a dosing pipe to form a dosing loop; the sampler is communicated with the sampling cavity through a sampling pipe to form a sampling loop; the valve control assembly comprises a drainage valve on the drainage loop, a dosing valve on the dosing loop and a sampling valve on the sampling loop; the monitoring assembly comprises a monitoring controller, and the monitoring controller is in communication connection with the valve control assembly so as to switch the drainage loop, the dosing loop or the sampling loop; and the monitoring controller is electrically connected with the dosing device to regulate and control the dosing amount. The drainage, dosing and sampling of pleural effusion can be realized on the premise that a pipeline is not disconnected.

The invention provides a matrigel-free culture method for lung adenocarcinoma malignant effusion tumor organs based on microcapsules, and belongs to the technical field of biomedicine. Through triple innovation of a material system (Ca < 2 + > sodium alginate < + > malignant effusion < + > droplet generation oil), a technical platform (a micro-fluidic chip) and a chemical mechanism (ion-triggered gelation), a brand-new lung adenocarcinoma organ culture method superior to a traditional scheme is constructed, and a lung adenocarcinoma organ microcapsule core-shell structure is stably obtained on the micro-fluidic chip. According to the method, the homogenized organoid can be automatically obtained on a large scale, and a stable and reliable practical tool is provided for drug screening, drug sensitivity testing and personalized medical treatment of lung cancer.

The invention provides a culture medium and a method for culturing malignant effusion specimen organs of epithelioid vascular endothelial tumor. The culture medium is added with 10-50ng / ml of CTGF for the first time. The culture method comprises the following steps: filtering a malignant effusion sample by using a 100 [mu] m filter screen, centrifugally collecting cells, embedding by using matrigel in a volume ratio of 1: 1, adjusting the cell density to 4 * 10 < 5 > / ml, and culturing for 12-16 days under the conditions of 37 DEG C and 5% CO2. The concentration of CTGF is crucial to the formation and growth of organoids, the optimal concentration value of 20ng / mL is obtained according to tests, the number of the organoids is large, the diameter of the organoids is large, the establishment rate of the organoids is successfully increased to 70% or above from less than 30%, the diameter of the obtained organoids reaches 120 + / -20 microns, the obtained organoids can be stably passed to P3 generations or above, and the gene characteristics and pathological phenotypes of primary tumors are reserved. The method is easy and convenient to operate, the modeling period is short (14 days), a reliable in-vitro model is provided for individualized drug sensitivity detection, drug screening and pathogenesis research of epithelioid vascular endothelioma, and the technical blank in the rare tumor research field is filled.